Compare DexCom, Inc. (DXCM) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs IONQ Inc — how do they compare? DexCom, Inc. trades at $83.83 (market cap $31.86B), while IONQ Inc trades at $39.27 (market cap $15.98B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and IONQ Inc for 33 Days on average.
| DXCM | IONQ | |
|---|---|---|
Market Cap | $31.86B | $15.98B |
Volume | 3,607,070 | 22,848,240 |
Sector | Health | Technology |
52-Week High | $92.34 | $82.09 |
52-Week Low | $54.84 | $26.59 |
Typical Hold Time | 62 Days | 33 Days |
Enterprise Value | $31.32B | $13.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
IONQ trades at $39.19, down 5.2% in the last session, with a bearish technical outlook despite recent positive analyst coverage. The quantum computing company shows explosive revenue growth (2025: $130M, 2026: $246M) but faces significant profitability challenges with a net income margin of -553.27%. Recent earnings showed mixed results with a Q2 2026 miss following two consecutive beats. The stock remains 50% below analyst consensus price target of $62.75, indicating substantial upside potential if execution improves.
IONQ presents a high-risk, high-reward opportunity with Wall Street divided (50% buy, 50% hold). The bullish case hinges on quantum computing leadership and partnerships with major cloud providers, while risks include persistent losses, cash burn, and execution challenges in a nascent market. Current valuation metrics (P/S: 54.74) reflect growth expectations rather than current fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
